Insulin

This page is an automatically generated summary of information from the Federal Court, Federal Court of Appeal, Health Canada and other websites. This information should NOT be relied upon as it is automatically generated and has not been confirmed for accuracy.

Automatically generated on February 8, 2020.

Return to the list of Patented Medicine Litigation page.





Insulin

APIDRA (10 mL Vial), APIDRA (3mL Cartridge), APIDRA (3mL OptiSet), APIDRA (3mL Solostar), APIDRA10mLVial, APIDRA3mLCartridge, APIDRA3mLOptiSet, APIDRA3mLSolostar, FIASP, HUMAJECT HUMALOG, HUMAJECT HUMALOG MIX25 / HUMALOG MIX25 PEN, HUMAJECT HUMALOG MIX50 / HUMALOG MIX50, HUMALOG, HUMALOG MIX25, HUMALOG MIX25 PEN, HUMALOG MIX50, HUMALOG MIX50 PEN, HUMALOG PEN, HUMALOGKWIKPEN, HUMALOGMIX50, LANTUS, LEVEMIR FLEXPEN, LEVEMIR INNOLET, LEVEMIR PENFILL, NOVOMIX 30, NOVOMIX 50, NOVOMIX 70, NOVORAPID, SOLIQUA, SOLIQUASOLIQUASOLOSTAR3060PEN, SOLIQUASOLOSTAR3060PEN, TOUJEODOUBLESTAR, TOUJEOSOLOSTAR – Eli Lilly Canada Inc. (NOC Search)

Patents:

  • 2490116: MYLAN

MYLAN


Return to the Patented Medicine Litigation page.

Canadian Intellectual Property